| Summary: | Glycophorin hybrids such as GP.Mur are common in Southeast Asians. In Taiwan, clinically significant alloantibodies to the GP.Mur phenotype are the most important issue in blood banks. A large-scale screening of glycophorin hybrids in the Taiwanese population is urgently needed to ensure transfusion safety. Four clones of human hybridomas that secrete anti-Mi<sup>a</sup>, anti-MUT, and anti-Mur were established by fusing human B-lymphocytes and myeloma cells (JMS-3). The specificity of each monoclonal antibody (MoAb) was characterized. Three MoAbs were applied on an Automated Pretransfusion Blood Testing Analyzer (PK7300/PK7400) for donor screening. Genotyping was performed to determine the detailed subgrouping of glycophorin hybrids. Four MoAbs are IgM antibodies. Anti-Mi<sup>a</sup> (377T) binds to <sup>46</sup>DXHKRDTYA<sup>54</sup>, <sup>48</sup>HKRDTYAAHT<sup>57</sup> peptides, and anti-Mi<sup>a</sup> (367T) binds to <sup>43</sup>QTNDXHKRD<sup>51</sup> peptides (X indicates T, M, or K). Anti-Mur is reactive with <sup>49</sup>KRDTYPAHTA<sup>58</sup> peptides. Anti-MUT is reactive with <sup>47</sup>KHKRDTYA<sup>54</sup>. A total of 78,327 donors were screened using three MoAbs, and 3690 (4.71%) were GP.Mur, 20 (0.025%) were GP.Hut, and 18 (0.022%) were GP.Vw. When the Mi<sup>a</sup> antigen was introduced as routine screening, the frequency of Mi(a+) among blood donors in Taiwan was 4.66% (67,348/1,444,541). Mi<sup>a</sup> antigen was implemented as a routine blood testing, and the results were labeled on all red blood cell (RBC) units.
|
|---|